Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ZOL Significantly Improves DFS Compared<br />
With Endocrine Therapy Alone<br />
Disease-free survival, %<br />
100<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
No. of Hazard ratio (95% CI)<br />
events vs No ZOL P value<br />
ZOL 54 0.643 (0.46, 0.91) .012<br />
No ZOL 83<br />
0 12 24 36 48 60 72 84<br />
Time since randomization, months<br />
No. at risk<br />
No ZOL 904 832 713 537 407 241 145 47<br />
ZOL 899 846 730 555 414 257 123 54<br />
Median follow-up = 48 months.<br />
DFS = Disease-free survival; CI = Confidence interval; ZOL = Zoledronic acid.<br />
Update of <strong>Gnant</strong> M, et al. Presented at: ASCO 20<strong>08</strong>. Chicago, IL. Abstract LBA4.<br />
10
Change language